Clovis Oncology, Inc.

CLVS | $0.0812 -3.94%

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (26.22% volume)
Earnings Calendar: 2023-02-22
Market Cap: $ 11,770,367
http://www.clovisoncology.com
Sec Filling | Patents | 484 employees

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

acquisitions cancer prostate cancer liver treatment cancer treatments

Drugs

Rubraca (rucaparib)

add to watch list Paper trade email alert is off

Horizon Therapeutics Public Limited Company

HZNP | $116.3 0.03% 29M

Health Technology

(0.0% 1d) (0.0% 1m) (5.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (383.01% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 26,632,068,258
http://www.horizontherapeutics.com
Sec Filling | Patents | 1200 employees

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

add to watch list Paper trade email alert is off

Lumos Pharma, Inc.

LUMO | $2.795 -0.18% -0.18% 46K

Health Technology

(0.0% 1d) (0.4% 1m) (-14.4% 1y) (0.0% 2d) (4.5% 3d) (11.1% 7d) (268.25% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 22,685,584
http://www.lumos-pharma.com
Sec Filling | Patents | 21 employees

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

hormone growth hormone treatment

add to watch list Paper trade email alert is off

Pacira BioSciences, Inc.

PCRX | $25.93 -3.28% -3.39% 360K

Health Technology

(0.0% 1d) (-8.3% 1m) (-39.6% 1y) (0.0% 2d) (2.7% 3d) (2.1% 7d) (32.5% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 1,206,346,187
http://www.pacira.com
Sec Filling | Patents | 606 employees

(US) Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

opioid injection

add to watch list Paper trade email alert is off

Electromed, Inc.

ELMD | $16.73 2.07% 0.0% 21K

Health Technology

(0.0% 1d) (-0.5% 1m) (56.1% 1y) (0.0% 2d) (4.3% 3d) (13.0% 7d) (34.93% volume)
Earnings Calendar:
Market Cap: $ 143,965,448
http://www.electromed.com
Sec Filling | Patents | 120 employees

Electromed, Inc. engages in the development, manufacture, marketing, and sale of medical equipment. It offers smartvest, and airways clearance system to patients with compromised pulmonary function. The firm focuses on building market awareness, and acceptance of its products and services with physicians, clinicians, patients, and third-party payers. The company was founded by Robert D. Hansen and Craig N. Hansen in 1992 and is headquartered in New Prague, MN.

electronics

add to watch list Paper trade email alert is off